A phase 2a Proof-Of-Concept Trial Investigating Pulsed Inhaled Nitric Oxide (iNO) To Treat Pulmonary Hypertension Associated With Idiopathic-Pulmonary-Fibrosis (PH-IPF)

Trial Profile

A phase 2a Proof-Of-Concept Trial Investigating Pulsed Inhaled Nitric Oxide (iNO) To Treat Pulmonary Hypertension Associated With Idiopathic-Pulmonary-Fibrosis (PH-IPF)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary hypertension
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Sep 2017 Status changed from recruiting to completed, according to a Bellerophon Therapeutics media release.
    • 22 May 2017 According to a Bellerophon Therapeutics media release, new clinical data from this study presented at the American Thoracic Society (ATS) 113th International Conference.
    • 22 May 2017 Primary endpoint has been met, according to a Bellerophon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top